New Malaria Vaccine Effective in Clinical Trial
February 15, 2017
(Science Daily) – University of Tübingen researchers in collaboration with the biotech company Sanaria Inc. have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ-CVac has been up to 100 percent effective when assessed at 10 weeks after last dose of vaccine. For the trial, Pro-fessor Peter Kremsner and Dr. Benjamin Mordmüller of the Institute of Tropical Medicine and the German Center for Infection Research (DZIF) used malaria parasites provided by Sanaria. The vac-cine incorporated fully viable — not weakened or otherwise inactivated — malaria pathogens together with the medication to combat them. Their research results have been published in the latest edition of Nature.